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ABSTRACT 
 
Catechol-O-methyltransferase (COMT), Cyclooxygenase (COX) 1 and 2 are 
enzymes that have been implicated in the modulation of pain. Previous studies have 
shown that human genetic variants coding for low COMT activity are correlated with 
increased experimental pain sensitivity and risk of developing chronic pain disorders. The 
present study extends this work by examining the potential contribution of three enzymes 
to acute pain perception. Ninety-four patients treated by endodontic residents at 
University of North Carolina School of Dentistry were enrolled into a prospective cohort 
study. Nonsurgical root canal therapy was performed. Participants recorded pain levels 
for five days following treatment and completed psychological questionnaires to quantify 
anxiety, depression and somatization disorders. Potential predictors of postoperative pain 
were collected and all patients submitted saliva samples for genetic analysis. In this 
study, 63% of patients experienced at least mild pain after root canal therapy and 24% 
experienced mild to severe pain. Patient age, gender, pulpal and periapical diagnosis were 
not associated with postoperative pain (p>0.05). Presence of pretreatment pain was 
significantly correlated with higher postoperative pain (p = 0.01). Diastolic blood 
pressure (p = 0.024), heart rate (p = 0.02) and trait anxiety score (p = 0.036) were also 
correlated with postoperative pain. While no association was found between 
postoperative pain and COMT or COX-1 genetic variants, there is evidence of an 
association between COX-2 haplotype and acute postoperative pain following endodontic 
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treatment (p = 0.025). Understanding the genetic basis of endodontic pain perception will 
advance our pharmacologic management of postoperative pain. 
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INTRODUCTION  
 
 
The general population commonly associates root canal therapy with pain, and 
postoperative pain remains a frequent sequelae of endodontic treatment. While many 
patients are asymptomatic following endodontic procedures, 15-30% of patients 
experience moderate to severe pain (Harrison et al.1983; Seltzer et al. 1961; Clem 1970), 
and up to 70% of patients report some discomfort postoperatively (Walton and 
Chiappinelli 1993; Sathorn et al. 2008; Selzer et al. 1961; Clem 1970).  The greatest level 
of postoperative pain usually occurs during the first 24 hours following endodontic 
treatment (Harrison et al. 1983; Albashareigh and Alnegrish 1998). High levels of 
preoperative pain are predictive of higher levels of discomfort both intra- and post-
operatively after endodontic therapy  (Harrison et al. 1983; Torabinejad et al. 1994).  
Individual variation in pain is likely due to a complex system of environmental 
factors and multiple gene polymorphisms.  Pulpal innervation and sensory pathways to 
the central nervous system are well described (Trowbridge 1985).  Signals transmit to 
higher-level brain regions for perception, including the reticular system, which is 
involved in emotions and psychosocial attitudes toward pain. This perception of pain in 
humans is influenced by both genetic and environmental factors. Genes have been 
implicated in animal studies to account for between 28 to 76% of pain perception (Mogil 
1999). However the genetic contributions to acute pain conditions such as postoperative 
endodontic pain remains unknown. 
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Genetic variants of the gene encoding catechol-O-methyltransferase (COMT), an 
enzyme regulating catecholamine metabolism, including catabolism of epinephrine, 
norepinephrine, and dopamine, have been associated with impaired regulation of pain in 
the central nervous system  (Nackley et al. 2007). Adrenergic systems contribute to the 
pathogenesis of rheumatoid arthritis in animals, as denervation of sympathetic 
noradrenergic fibers  (Levine et al.1986) and depletion of peripheral epinephrine  (Coderre 
et al.1990) attenuate inflammatory and arthritic responses. Additionally, chronic 
administration of β-adrenergic receptor (βAR) agonists produces a painful arthritis-like 
syndrome  (Vyden and Corday 1971). These findings are consistent with clinical 
observations that sympathetic blockade or administration of the βAR antagonist 
propranolol delays the onset and reduces the severity of arthritis and joint responses to 
injury (Kaplan et al.1980; Levine et al. 1986; Baerwald et al.1997). These abnormalities 
are associated with diminished activity of COMT in erythrocytes. Furthermore, COMT 
activity has been proposed to affect µ-opioid receptor function by influencing the 
bioavailability of dopamine (Zubieta et al. 2003; Rakvag et al. 2005). Collectively, these 
results suggest that elevated catecholamime levels promote persistent pain states. 
There are two basic forms of COMT: soluble COMT (S-COMT) and membrane 
bound COMT (MB-COMT). While S-COMT and MB-COMT share many common 
structural characteristics, they exhibit different kinetic properties. At physiological 
concentrations, MB-COMT appears to be the primary form of the enzyme that 
metabolizes dopamine, epinephrine, and norepinephrine (Tenhunen et al. 1994). Both S-
COMT and MB-COMT are coded for by a single gene (Mannisto & Kaakkola 1999). 
(See Figure 1). They are encoded as two separate transcripts, and in most human tissues 
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both transcripts are present. The expression of COMT varies across several tissues, 
suggesting it is regulated by some tissue specific transcription factor.  In fact, the human 
COMT gene locus contains several putative regulatory binding sites (Tenhunen et al. 
1994; Xie 1999). 
  Previous studies reveal that there is a substantial amount of polymorphism within 
the COMT gene. There are approximately 125 SNPs, and 11 of these have a minor allele 
frequency of more than 35%. Originally, a common SNP in codon 158 (val158met) of 
COMT had been proposed to contribute to differences in the human experience of pain 
(Zubieta et al. 2003).  This functional polymorphism in the COMT gene codes for a 
substitution of valine (val) by methionine (met).  The methionine substitution produces a 
COMT enzyme that has lower thermostability resulting in decreased enzyme activity  
(Lotta et al. 1995).  It was generally accepted that genetic variability in codon 158 was 
the main source of individual variation in COMT activity in humans. Numerous studies 
have identified associations between the low activity met allele and several complex 
behavioral disorders and physical diseases (Mannisto & Kaakkola 1999). However, in 
many cases the observed associations between these conditions with the met allele (low 
enzyme activity) are relatively modest and occasionally associated with contrary findings 
(Mannisto & Kaakkola 1999). This suggested the possible involvement of other SNPs in 
the COMT gene that additionally modulate COMT activity and consequently contribute 
to the individual differences in pain perception. This hypothesis led to identifying four 
main single nucleotide polymorphisms (SNPs) found within COMT alleles that, when 
combined, formed three major haplotypes. These three haplotypes had much stronger 
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associations with individual pain sensitivity than val158met and explained ~ 11 % of the 
overall variability in the test population’s sensitivity to pain (Diatchenko et al. 2005). 
The three main haplotypes identified account for 95.9% of COMT variation in 
humans. These haplotypes were found to explain variations in COMT activity and can be 
used to explain experimental pain sensitivity. Specifically, the haplotypes associated with 
heightened pain sensitivity (HPS) produce lower COMT activity. In a prospective cohort 
study at the University of North Carolina at Chapel Hill, the three most prevalent 
haplotypes encoding COMT were associated with experimental pain perception and were 
significant risk factors for development of temporomandibular disorder (TMD) 
(Diatchenko et al. 2005).  In 2006 the specific pathway through which reduced COMT 
activity produces heightened pain sensitivity was further elucidated.  It was found that 
COMT inhibition increases pain sensitivity through activation of adrenergic receptors 
(Nackley et al. 2007).  
Cyclooxygenase (COX) is another enzyme that plays an important role in the pain 
process. Non-steroidal anti-inflammatory drugs (NSAIDs) have a well-established 
analgesic efficacy for inflammatory pain, which effectively manages postoperative 
endodontic pain.  The major analgesic mechanism for NSAIDs is the inhibition of COX-1 
and COX-2  (Polisson 1996).  Cyclooxygenase 1 and 2 are both induced during 
inflammation. While COX-1 is expressed constituently and has homeostatic functions, 
COX-2 is an inducible enzyme that produces pro-inflammatory prostaglandins (PGs). A 
study by Khan et al. (2007) examined the in vivo expression of COX-1 and COX-2 
before and after removal of impacted mandibular third molars. They demonstrated a 
significant, progressive increase postoperatively in the level of COX-2 mRNA over time 
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compared to preoperative levels. The results definitively demonstrated increased 
expression of COX-2 in acute inflammation. The corresponding increase in PG levels 
contribute to postoperative pain levels. Wide inter-individual variability in COX-1 and 
COX-2 gene expression has been shown. Functional polymorphisms in the COX-2 gene 
may explain the variations in acute pain and in the analgesic efficacy of NSAIDs in 
different people (Lee et al. 2006). 
Pain is a multifactorial process, which is influenced by physiological, 
psychosocial, and genetic factors. Despite suggestive evidence that genetic 
polymorphisms in catechol-O-methyltransferase (COMT) and cyclooxygenase (COX) 
influence pain sensitivity, their exact roles in the perception of acute postoperative pain in 
humans are currently unknown. We conducted a study to examine how various 
phenotypic factors contribute to pain after endodontics and also whether a genetic 
association could be identified between COMT polymorphisms and an acute pain 
condition. The association between COX-1 and COX-2 genotype and postoperative pain 
perception was also assessed. Discovering the underlying etiology for the variation in 
patients’ pain perceptions is significant for managing endodontic pain through 
pharmacologic and procedure-based therapies. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
 
A. Postoperative Pain in Endodontics 
 Postoperative pain is a common sequelae of root canal therapy. A recent 
systematic review found the prevalence of postoperative pain to range widely, from 3% 
to 58% in sixteen included studies (Sathorn et al. 2008). A study by Seltzer, Bender and 
Ehrenreich (1961) studied 698 patients submitted by 6 different dentists and reported 
incidence of postoperative pain to be a very wide range, between 9% and 57%, with an 
overall incidence of severe pain being 20%. Harrison et al. (1983) studied 229 patients 
and found that 47.6% reported postobturation pain. Thirty-four percent of patients 
reported slight pain and 14% reported moderate to severe pain, defined as pain requiring 
medication or other palliative treatment. In 1970 Clem reported in a study of 318 subjects 
that 39% reported mild pain and 25% of patients experienced moderate pain after root 
canal treatment. A similar study of 245 patients treated by undergraduate dental students 
found that 32% had no pain, 21% had slight pain, 30% had moderate pain, and 17% had 
severe pain following chemomechanical preparation of the root canal (Georgopoulou et 
al.1986). Walton and Chiappinelli (1993) reported one of the highest incidences of 
subjects with post-treatment discomfort at 70%; the overwhelming majority of these were 
in the mild range and occurred soon after treatment. Incidence after nonsurgical 
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retreatment is similar to most studies of initial RCT, with about 40% of patients reporting 
pain (Kvist and Reit 2000).  
Postoperative pain is an acute process, which gradually subsides over the course 
of a few days. Harrison et al. (1983) found a statistically significant higher incidence and 
degree of postobturation pain during the first 24 hours after treatment. Albashaireh and 
Alnegrish confirmed this result in a study of 291 patients receiving RCT, finding that 
pain incidence is greatest during the first 24 hours and quickly decreases thereafter. 
While 33% of their subjects experienced pain on postoperative day one, only 2% reported 
pain on day 7 postoperative (1998).  
 
B. Factors Associated with Endodontic Pain 
 Many studies have attempted to identify factors that affect postoperative 
pain, however very few such factors have been shown to be consistently significantly 
associated. Factors proposed to contribute to postoperative pain after endodontic 
treatment include patient age, patient gender, tooth type treated, pulpal diagnosis and 
periapical diagnosis (Seltzer et al. 1961; O’Keefe 1976; Oguntebi et al. 1992; Clem 1970; 
Georgopoulou et al. 1986; Albashaireh and Alnegrish 1998; Siqueira et al. 2002; 
Marshall and Liesinger 1993)  .  
Seltzer et al. (1961) found an association of post-operative pain and age, with 
patients under 21 years old experiencing less pain than older patients. O’Keefe (1976) 
also found significantly greater moderate and severe pain after treatment for those 20 
years and older.  However a large retrospective study found a lower incidence in post-
treatment pain in older age groups (Oguntebi et al. 1992). Most studies found no 
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difference between age groups (Clem 1970; Georgopoulou et al. 1986; O’Keefe 1976; 
Albashaireh and Alnegrish 1998). Patient gender has also been proposed as a significant 
factor in the development of pain after root canal therapy. However almost all studies 
have shown no significant difference in pain reporting between males and females (Clem 
1970; Georgopoulou et al.1986; O’Keefe 1976; Albashaireh and Alnegrish 1998). Studies 
have also failed to show subject race as a significant factor for the development of 
postoperative pain after endodontics (O’Keefe 1976). 
In 1970, Clem found an association between tooth types treated, with mandibular 
molars being involved in pain experience twice as often as maxillary teeth. Other studies 
have failed to reproduce this association (Georgopoulou et al. 1986; O’Keefe 1976). 
Pulpal diagnosis may or may not have an affect on postoperative pain. A 1998 study 
found that root canal treated teeth with vital pulps had significant lower frequency of pain 
(9%) than those with nonvital pulps (41%) (Albashaireh and Alnegrish 1998). However 
preoperative pulpal diagnosis has not been shown in other studies to be associated with 
postoperative pain experience after RCT (Clem 1970; Georgopoulou et al. 1986; O’Keefe 
1976).  
Periapical diagnosis, and specifically the presence or absence of periapical 
radiolucent lesions, has not consistently been shown to be correlated with postoperative 
endodontic pain. Georgopoulou et al. (1986) found no difference in pain incidence 
between teeth with or without periapical radiolucencies. O’Keefe (1976) also failed to 
find a significant association between postoperative pain and presence of an apical 
radiolucency. However Siqueira et al (2002) examined the incidence of postoperative 
pain after intracanal debridement and found of 627 treated teeth only 10% of cases 
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resulted in moderate pain and 5% in moderate or severe pain; they did find, in contrast to 
previous studies, that pain was significantly associated with the treatment of teeth without 
periradicular lesions. Marshall and Liesinger (1993) found a similar result, with patients 
with no radiographic periapical lesions having significantly more pain than patients with 
lesions at all post-treatment time points.  
 The only pretreatment parameter that consistently is seen to be associated with 
postoperative pain incidence is the presence of preoperative pain. A prospective study of 
588 nonsurgical root canal therapy patients by Torabinejad et al. (1994) assessed the 
severity of pain using a visual analogue scale for 72 hours after instrumentation. The 
study found only three tested parameters to be significantly associated with post-
operative pain following instrumentation: presence of preoperative pain, patient 
apprehension, and type of medication taken postoperatively. A strong association was 
found between the intensity of preoperative pain and the incidence of severe post-
operative pain. Only 7% of patients who had no preoperative pain developed severe pain 
after chemo-mechanical debridement of the root canals; the incidence increased to 51% 
in patients with severe preoperative pain. In 1976, O’Keefe showed a similar significant 
relationship in endodontic patients; those with moderate or severe preoperative pain were 
five times more likely to have moderate or severe postoperative pain.  Genet et al. (1986) 
also found a strong positive correlation between the presence of preoperative pain and the 
incidence of postoperative pain. 
 
C.  Etiologies of Postoperative Endodontic Pain  
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Pulpal innervation and sensory pathways to the central nervous system are well 
described (Trowbridge 1985). Signals transmit to higher-level brain regions for 
perception, including the reticular system, which is involved in emotions and 
psychosocial attitudes toward pain. The presence of inflamed periapical tissues causes 
postoperative pain or discomfort (Torabinejad et al. 1994). The exact mechanisms for 
pain after endodontics remain unknown. Several theories of mechanisms involved in pain 
after instrumentation of root canals exist, which were outlined in a review paper by 
Seltzer et al. in 2004. He proposed the following major mechanisms for how post-
operative pain occurs: (1) Alteration of asymptomatic periapical lesions in the form of 
medicaments, irrigating solutions or tissues proteins introduced into the lesion, (2) 
Changes in periapical tissue pressure due to excessive exudates putting pressure on nerve 
endings, (3) Anaerobic microbes producing endotoxins from infected root canals 
increasing vasoactive transmitter substances at nerve endings in periapical lesions and (4) 
Proinflammatory mediators such as histamines, prostaglandins, leukotrienes, bradykinin 
that are released when the root canal is instrumented.  
 Several factors inherent to the infected root canal and treatment technique used to 
manage it have been proposed by other authors. These include overinstrumentation of the 
canals (Harrison et al. 1983), extrusion of debris and microorganisms into the periapical 
tissues (Bystrom and Sundqvist 1985), changes in periapical pressure following root 
canal therapy (Mohorn et al. 1971), the presence of certain anaerobic bacterial species 
(Griffee et al. 1980; Gomes et al. 2008), endotoxin (Schonfeld et al.1982) and 
inflammatory by-products (Seltzer and Naidorf 1985).  
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D.  Peripheral and Central Mechanisms of Pain  
  Nociceptive endings present in the pulp and periapical tissues arise from A-δ 
fibers, which respond to painful mechanical stimuli, and C-fibers, which transmit dull 
pain (Merrill 2007). A-β mechanoreceptors normally encode only low frequency, non-
noxious stimuli that are perceived as light touch (Torebjork 1992). The A-δ and C-fiber 
nociceptors are activated by a variety of noxious stimuli, and peripheral sensitization 
occurs when the thresholds are lowered by repeated stimulus from noxious sources.  For 
example in an extracted tooth site, inflammatory mediators are released which sensitize 
nociceptors, which leads to the inflamed area being marked by increased pressure 
sensitivity (Merrill 2007). These peripheral mechanisms play major roles in producing 
hyperalgesia, increased pain response to noxious stimulus, and allodynia, a painful 
sensation due to a stimulus that is normally innocuous (Matthews and Sessle 2008). The 
release of potassium ions, substance P, bradykinin, and prostaglandins induce the 
sensitization of peripheral receptors and therefore the characteristics of primary afferent 
fibers change (Curatolo et al. 2004).  If the inflammatory process continues at a sufficient 
intensity, a central process occurs that lowers the response threshold.  Additionally, A-β 
fibers now begin signaling pain, adopting C-fiber characteristics, which is a form of 
allodynia (Neumann et al. 1996; Merrill 2007). An increase in central release of 
excitatory mediators such as glutamate and nitric oxide production also takes place; 
changes in mRNA then genetically alter nociceptors and mechanoreceptors to a 
pathologic state (Merrill 2007).  
Central sensitization, defined as an increased responsiveness of neurons in the 
central nervous system, is a form of neuroplasticity in which nociceptor activity leads to 
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an increase in the excitability of dorsal horn neurons (Merrill 2007).  The process is 
initiated by a burst of C-fiber activity. C- nociceptors are primarily involved in the 
initiation of central sensitization by causing an increased rate of depolarization in the 
dorsal horn (Thompson et al. 1993). The process proceeds due to a nociceptive afferent 
barrage leading to prolonged functional alteration (Chiang et al. 1998). The chemical 
mediators involved in this barrage include glutamates and neuropeptides such as 
substance P and calcitonin-gene related peptide (CGRP), which prolong depolarization of 
the neurons and increase their excitability via glutamate and G-protein coupled receptors 
(Sessle et al. 2008). It has been shown in animal studies that the central sensitization 
occurring in the tooth pulp functions via the glutametergic and purinergic P2X receptors 
(Chiang et al. 1998). Studies have shown that the intensity of the noxious input will 
influence the degree of central sensitization (Iwata et al. 1986; Ji et al. 2003).  
The classically described mechanism for central sensitization involves release of 
neurotransmitters in the CNS from C-fiber nociceptors that causes a cascade of second-
order neuron events, such as NMDA receptor activation and ion channel opening.  
Calcium then flows into wide dynamic range neurons, leading to the formation of nitric 
oxide. Nitric oxide diffuses out of the postsynaptic neuron, further stimulating 
presynaptic release of excitatory amino acids and neurokinins to continue the process 
(Merrill 2007).  
Glial cells (microglia and astrocytes) have been proposed to play a role in central 
sensitization. While in the past glial cells have been thought of as passive support cells, 
they are now believed to be active participants in modulating pain transmission in the 
CNS.  These cells have been shown to be involved in central sensitization of neurons in 
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the trigeminal subnucleus caudalis in the medullary dorsal horn, via release of cytokines 
and tumor necrosis factor (Xie et al. 2006).  It is also proposed that glia can respond to 
central neurotransmitter release from presynaptic nociceptor endings (Inagaki et al. 
1991).  Glial cells have been shown to be involved in development of hyperalgesia due to 
conditions that can lead to central sensitization (Colburn and DeLeo 1999).  
Clinical studies of central sensitization have been studied in a variety of pain 
conditions.  Using whiplash injury as a model for a chronic pain condition, one study 
found lower pain thresholds in subjects versus healthy controls despite the absence of 
tissue damage at the site of experimental testing, suggesting central sensitization of 
nociceptor pathways as the cause of hypersensitivity (Sheather-Reid and Cohen 1998).  
Koelback et al. (1999) found that whiplash patients had higher pain scores, longer 
duration of pain, and larger areas of local and referred pain versus healthy subjects, after 
intramuscular injection of saline.  Curatolo et al. (2001) examined pain thresholds to 
electrical stimuli in whiplash patients and healthy controls, and found that case subjects 
displayed lower pain thresholds.  These studies suggest that patients with chronic pain 
after whiplash display pain hypersensitivity after stimulation of normal tissues, which is 
likely a result of alterations in CNS processing of the sensory input.  
Another pain condition in which central sensitization has been studied is TMJ. 
Maixner et al. (1995) showed that relative to pain free control subjects, patients with TMJ 
had significantly lower thermal and ischemic pain thresholds and ischemic pain tolerance 
values.  The study attributed this result in part to the view that TMJ is mediated by 
alterations in the CNS, rather than peripheral mechanisms.  Another study of 36 TMJ 
patients found that grouping patients into pain-sensitive or pain-tolerant, depending on 
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their ischemic pain tolerance, resulted in clinically relevant differences in pain sensitivity 
(Fillingim et al. 1996); the findings were consistent with the hypothesis that CNS 
inhibitory pathway impairments contribute to pain in TMJ conditions. Temporo-
mandibular joints can develop both peripheral and central neuropathy, leading to an 
increase of pain when intracapsular injections are attempted to relieve joint inflammation 
(Merrill 2007), supporting a contribution of central sensitization.   
 Central sensitization can last for days or longer, and is thought to be a contributor 
persistent, spontaneous dental pain (Sessle et al. 2008), such as that which occurs after 
root canal therapy. Clinical procedures in dentistry such as third molar extraction have 
been shown to partly mediate the central component of both hyperalgesia and allodynia 
post-operatively. In a study by Juhl et al. (2008) thirty-two men were tested in the 
trigeminal area of the CNS for up to 30 days following impacted third molar extraction; 
the study found clear signs of central sensitization of the trigeminal nociceptive system 
for at least one week post-operatively.  Orofacial pain conditions, such as prolonged pain 
after root canal therapy, likely involve a mixture of peripheral and central sensitization 
(Sessle et al. 2008). The majority of clinical studies that examine factors associated with 
postoperative endodontic pain agree that the presence of preoperative pain is an important 
predictor of pain after root canal therapy (Torabinejad et al. 1994; O’Keefe 1976; Genet 
et al. 1986). This acute postoperative pain is likely due in part to the process of central 
sensitization. However, the specific role of central sensitization as a predictor for pain in 
the postoperative period following endodontic therapy has not been determined. Further 
studies are needed to better understand both the development and resolution of central 
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sensitization in endodontic patients, in order to more effectively manage postoperative 
pain.  
 
 
E. Genetic Contributions to Pain 
While a variety of physiological factors contribute to the variability of pain both 
experimentally and clinically, the role of genetic factors in human pain sensitivity is 
increasingly being recognized as an important element. An expanding number of genetic 
variants have been identified that are associated with pain, which is in line with the 
multifactorial nature of clinical pain phenotypes (Diatchenko et al. 2007).  
While it is established that pain is a multifactorial process, influenced by genetic and 
environmental factors, the extent to which genetics contribute to human pain perception 
remains unclear. A review article by Mogil (1999) reported that heritability for 
nociceptive sensitivity in mice is between 28 and 76%.  His own study using 11 different 
genetic mouse strains tested pain on a variety of dimensions, including acute nociceptive 
and inflammatory pain. The results of this study showed that in certain pain assays, 
within-cluster genetic correlations exceeded between cluster correlations, supporting a 
potential genetic contribution to pain in rodent models (Mogil et al. 1999).  
 A variety of genes have been proposed to contribute to experimental pain 
sensitivity in humans. Kim et al (2004) studied a total of 500 male and female subjects of 
varied ethnic backgrounds and found that Caucasian females with TRPV1 Val(585) Val 
allele in the vanilloid receptor subtype 1 gene showed greater pain tolerance to 
experimental cold. An SNP on the delta opiod receptor subtype 1 gene (OPRD1) also 
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contributed to individual variation in thermal and cold pain sensitivity. The same research 
group (Kim et al. 2009) recently published a genome-wide association study of acute 
post-surgical pain in humans, and discovered by SNP genotyping of over 100 male and 
female subjects a candidate SNP (rs2562456) that was associated with analgesic onset in 
zinc finger protein (ZNF) 429. They also located a candidate loci for postoperative pain, 
rs17122021, that suggests that genetic variations in loci encoding DNA binding proteins 
play a role in acute pain. Other studies have looked at whether an A118G SNP in the mu-
opiod receptor (MOR) gene could explain the inter-individual differences in acute 
postoperative pain; however no statistically significant association was found between the 
presence of the polymorphism and average postoperative pain scores (Janicki et al. 2006).  
 
F.  Properties of Catechol-O-methyltransferase 
While an increasing number of genetic variants associated with clinical pain 
phenotypes are being identified, Catechol-O-methyltransferase (COMT) has been 
specifically confirmed as a pain-modulating enzyme. Catecholamine neurotransmitters 
such as dopamine, norepinephrine and epinephrine are termed monoamine 
neurotransmitters. They operate through G protein-coupled receptors and second 
messenger systems to regulate the responsiveness of a large area of brain circuitry, 
including neural systems involved in higher brain functions such as emotion and 
cognition. These molecules are catabolized enzymatically, however, their functional 
activity is terminated primarily by their reuptake into the nerve terminal. COMT is 
among the genes encoding molecules involved in the monoamine neurotransmitter 
system (Zubieta et al. 2003).  
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There are two basic forms of COMT, soluble COMT (S-COMT) and membrane 
bound COMT (MB-COMT). While S-COMT and MB-COMT share many common 
structural characteristics, they exhibit different kinetic properties. At physiological 
concentrations, MB-COMT appears to be the primary form of the enzyme that 
metabolizes dopamine, epinephrine, and norepinephrine (Tenhunen et al. 1994). 
Both S-COMT and MB-COMT are coded for by a single gene (Mannisto and 
Kaakkola 1999). (See Figure 1). They are encoded as two separate transcripts. In most 
human tissues both transcripts are present. The observation that the expression of COMT 
varies across several tissues suggests that it is regulation by a tissue specific transcription 
factor.  In fact, the human COMT gene locus contains several putative regulatory binding 
sites (Tenhunen et al. 1994; Xie et al.1999).  
Previous studies reveal that there is a substantial amount of polymorphism within 
the COMT gene. There are approximately 125 SNPs, among which 11 of these have a 
minor allele frequency of more than 35%. Originally, a common SNP in codon 158 
(val158met) of COMT had been proposed to contribute to differences in the human 
experience of pain (Zubieta et al. 2003), anxiety (Enoch et al. 2003) and bipolar disorder 
(Domschke et al. 2004).  This functional polymorphism in the COMT gene codes for a 
substitution of valine (val) by methionine (met).  The methionine substitution produces 
COMT enzyme that has lower thermostability resulting in decreased enzyme activity. 
(Lotta et al.1995).  The genetic variability in this codon is the established primary source 
of COMT activity variations among human individuals (Mannisto and Kaakkola 
1999).The val(158)met SNP has been shown to play a primary role in individual variation 
in temporal summation of pain in a controlled clinical study (Diatchenko et al. 2006).  
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It was generally accepted that genetic variability in codon 158 was the main 
source of individual variation in COMT activity in humans. Numerous studies have 
identified associations between the low activity met allele and several complex 
behavioral disorders and physical diseases (Mannisto and Kaakkola 1999). However, in 
many cases the observed associations between these conditions with the met allele (low 
enzyme activity) are relatively modest and occasionally associated with contrary findings 
(Mannisto and Kaakkola 1999). This suggested the possible involvement of other SNPs 
in the COMT gene that additionally modulate COMT activity and consequently 
contribute to the individual differences in pain perception. The hypothesis led to 
identifying four main SNPs that, when combined, formed three major haplotypes. These 
three haplotypes had much stronger associations with individual pain sensitivity than 
val158met and explained ~ 11 % of the overall variability in the test population’s 
sensitivity to pain (Diatchenko et al. 2005). Diatchenko et al described five combinations 
of the three haplotypes that were detected in 92% of study subjects. Different haplotype 
combinations corresponded to different levels of pain sensitivity. Subjects who were 
homozygous for the “low pain sensitivity” (LPS) haplotype had the lowest pain 
responsiveness. Intermediate pain responsiveness was observed for individuals 
homozygous for the “average pain sensitivity” (APS) haplotype.  The greatest pain 
responsiveness was observed for individuals heterozygous for the APS haplotype and 
“high pain sensitivity” (HPS) haplotype. 
 
G.  Catechol-O-methyltransferase and Pain 
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 Polymorphisms in COMT has been shown to be correlated with pain in vitro, in 
animal studies, and in humans with both experimental and chronic pain conditions. The 
mechanisms for COMT’s contribution to pain have also been elucidated. The role of 
COMT in acute pain conditions has recently been studied clinically.  
In 2005 Diatchenko et al. explored in vitro how functional polymorphisms of 
COMT determine enzyme activity by transfecting HEK 293 cells with COMT cDNA 
clones corresponding to the HPS, APS, and LPS haplotypes. They demonstrated that the 
HPS haplotype produces 11 times lower COMT activity compared to the LPS haplotype, 
which they attributed to a difference in efficiency of protein synthesis (Diatchenko et al. 
2005). Nackley et al. (2006) showed that protein translation is regulated by an interaction 
between three alleles in the COMT haplotypes. The three different haplotypes-  HPS, 
APS, and LPS-- varied in mRNA structure stability, and the lowest COMT protein levels 
and enzymatic activity were associated with the most stable structures. Other studies have 
suggested mechanisms by which COMT contributes to the pathogensis of inflammatory 
pain states. An in vitro study by Tchivileva et al. (2009) reported that TNFalpha, present 
in inflammatory states, downregulates COMT mRNA and protein in certain cells. NF-
kappaB, the target of TNFalpha and an important regulator of inflammation, binds to 
COMT and inhibits expression in the CNS.  
Animal research has confirmed the association between COMT and pain. The 
Diatchenko et al. study (2005) found that reductions in COMT enzymatic activity 
enhanced pain sensitivity in rats. Another study by Nackley et al (2007) identified how 
COMT inhibition increased pain sensitivity. Rats were administered a COMT inhibitor 
(mimicking the effects on the HPS haplotype), and responses to mechanical and thermal 
 20 
 
stimuli were measured. They found that low COMT activity caused pain sensitivity 
through activation of the beta2-and beta3- adrenergic receptors (βARs).  
The association of COMT genetic polymorphisms and experimental pain has been 
shown in humans. Diatchenko et al. in 2006 examined the association between the three 
common COMT haplotypes and various experimentally painful stimuli.  LPS/LPS 
homozygotes had the least pain responsiveness to thermal, ischemic, and mechanical 
stimuli, and APS/HPS heterozygotes had the greatest pain responsiveness; the APS/APS 
homozygotes were average.  
Finally, several authors have identified a link between COMT genetic variations 
and chronic pain conditions in humans. Diatchenko et al. (2005) illustrated the 
relationship between COMT polymorphism, pain sensitivity, and the risk of TMD 
development. The clinical portion of the study involved 170 female volunteers 
prospectively followed for three years. The study confirmed that HPS and/or APS 
subjects were more sensitive to experimental pain at baseline and the incidence rate of 
TMD was more than twice as high compared with LPS subjects. Persistent facial pain 
patients have been reported to have lower COMT activity, as demonstrated by Marbach 
and Levitt (1976). A study by Slade et al. in 2008 followed a prospective cohort of 186 
females and found that subjects with a variant of the gene encoding COMT were at 
significantly greater risk for developing TMD if they had a history of orthodontic 
treatment. Their findings suggest that this COMT variant could help identify patients 
whose risk of TMD after orthodontic treatment is increased.  
Information on the correlation between COMT genotypes and acute pain states 
such as postoperative endodontic pain is limited. Kim et al. (2006) examined the effects 
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of variations in COMT on acute clinical pain responses in humans and found a significant 
association with maximum postoperative pain ratings; however they were not able to 
sustain the genetic associations when the data was corrected for multiple comparisons. In 
their study of approximately 112 male and female patients, they determined that genetic 
polymorphisms in the monoamine neurotransmitter systems, including COMT, contribute 
only weakly to interindividual variability in postoperative pain after third molar 
extraction. 
 
H.   Properties of Cyclooxygenase 
Other potential candidate genes for pain modulation include COX-1 and COX-2. 
Cyclooxygenase 1 (COX-1; prostaglandin H synthase1; PTGS1) is the main enzyme 
involved in the synthesis of prostaglandin H2 from arachidonic acid, which is the 
committed step in PG synthesis. The functional COX-1 protein is 576 amino acids long, 
composed of 11 exons, on chromosome 9; the promoter has multiple binding sites for 
transcription factors that are essential for activity of the enzyme (Wang et al.1993) (See 
Figure 2). COX-1 is a constitutively expressed enzyme that functions in the production of 
PGs with homeostatic function in many different human tissues, whereas 
Cyclooxygenase 2 (COX2; prostaglandin H synthase2; PTGS2) is inducible and has a 
role primarily in the production of PGs that promote inflammation (Khan et al. 2007). 
The 2 isoforms of cyclooxygenase have different half-lives—COX-1 mRNA has a half-
life of about 12 to 15 hours, while the COX-2 half-life is less than 3.5 hours; this 
indicates a link between tissue injury and COX-2 expression, as opposed to COX-1.  It 
has been shown that proinflammatory cytokines and endotoxins can lead to an increase in 
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COX-2 levels in inflammatory cells 10 to 80 fold. (Khan et al. 2007). The 
cyclooxygenases are also the primary targets of aspirin and non-steroidal anti-
inflammatory drugs (NSAIDs) and thus of major interest in the management of 
inflammatory pain.  
Genetic variations of COX-1 and COX-2 have been described in several studies. 
Ulrich et al. (2002) screened the gene coding regions of COX-1 in 94 subjects and 
identified 13, mostly rare, coding-region variants including 7 amino-acid substitutions. 
Genetic software programs identified 2 COX-1 substitutions likely to impact the function 
of COX-1, which were the L237M substitution and a glycine at position 230. The role of 
these genetic variations in COX-1 relative to the function of the gene has been studied. 
Thirty-eight healthy subjects had their promoter and cDNA sequenced to search for 
polymorphisms; 9 such SNPS were identified. Two of these SNPs resulted in altered 
proteins that potentially affected function; however no common variants affecting the 
structure and function of COX-1 were found (Halushka et al. 2003).  
While it has been proposed that polymorphisms in both COX-1 and COX-2 could 
alter gene expression and function, studies have reported mixed results. An investigation 
of the COX-2 gene for functional variants found that a common COX-2 promotor variant, 
-765G>C, was found to be carried by 25% of subjects and the -765C had significantly 
lower promoter activity compared to -765G (Papafili et al. 2002).  However in another 
study by Fritsche et al. (2001) the COX-2 gene of 72 subjects was sequenced and rare 
polymorphisms were identified; this study found no differences between the COX-2 wild 
types and the mutant forms in terms of Km values for arachidonic acid or difference in 
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inhibition with nonselective COX inhibitors. No functionally important polymorphisms 
in the COX-2 gene were identified (Fritsche et al. 2001).  
A study by Lee et al. (2006) compared subjects before and after third molar 
extraction surgery, and found that COX-1 expression (though relatively higher than 
COX-2 expression) was decreased (36%, p < 0.001) and COX-2 expression was 
considerably increased (300%, p < .001) at 2 to 4 hours postoperative. Both enzymes 
returned to presurgical levels at 2 days postoperatively. Moreover, the authors 
demonstrated a wide interindividual variation in expression of the genes, with a greater 
that 2-fold decrease observed in some patients and a 2-fold increase seen in others. In 
terms of gene expression, while no significant association was found between genetic 
variations of COX-1 and its expression, a genetic variation at an SNP at position -765 in 
the promoter region of COX-2 resulted in significantly altered functional expression. The 
authors concluded that functional polymorphisms in the COX-2 gene may explain the 
interindividual variations in acute pain and the analgesic efficacy of NSAIDs. 
 
I.   Cyclooxygenase, NSAIDs, and Postoperative Pain  
A proposed mechanism of pain involves the activation of nociceptors by release 
of inflammatory mediators in the periapical tissues. NSAIDs are the foremost 
pharmaceuticals used to manage acute dental pain in general, and have been critically 
evaluated in the treatment of endodontic pain specifically. Knowledge of the 
pharmacology of NSAIDs in a clinical setting is largely based on studies using the oral 
surgery (third molar extraction) model for acute pain (Cooper & Beaver 1976). Dionne 
and Berthold believe that this model can be extrapolated to pain of endodontic origin 
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(2001). Iburpofen is the prototypical NSAID and is the drug of choice among 
endodontists for postoperative pain relief (Torabinejad et al.1994).  
A study by Khan et al. (2007) examined the in vivo expression of COX-1 and 
COX-2 before and after removal of impacted mandibular third molars. Forty-three 
patients were randomly distributed among one of four treatment groups, ranging from 
zero to 120 minutes post-surgery. Their results demonstrated little or no COX-2 
expression preoperatively, as opposed to the COX-1 transcript which was detected in all 
preoperative and postoperative specimens. They confirmed the results of previous studies 
showing a significant, progressive increase postoperatively in the level of COX-2 mRNA 
over time compared to preoperatively. The results definitely demonstrated increased 
expression of COX-2 in acute inflammation. The corresponding increase in PG levels 
influences postoperative pain levels.  
NSAIDs exert the majority of their effects through nonselective inhibition of the 
COX enzymes. The mechanism by which ibuprofen functions in postoperative 
endodontic pain is by inhibiting prostaglandin production over the initial 48- 72 hours 
postoperative, when the inflammatory process is most active. Ibuprofen manages this 
pain well because several pro-inflammatory mediators are released during endodontic 
treatment that may contribute to postoperative discomfort (Dionne and Berthold 2001).  
While ibuprofen is considered an effective drug for managing pain in endodontic 
patients, a prospective study of 57 patients there was no significant difference in pain 
relief in patients taking 600mg ibuprofen versus placebo (Menhinick et al. 2004). 
Torabinejad et al. (1994) in a study of 411 subjects also found that none of the 9 drug 
groups they tested could be differentiated from placebo for pain after root canal 
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obturation; however, only 4% of their sample developed moderate or severe pain, which 
may reflect a lack of assay sensitivity for this model (Dionne and Berthold 2001).  
In addition to ibuprofen, selective COX-2 inhibitors have been proposed as a 
therapeutic alternative for acute pain conditions such as postoperative endodontic pain. 
Based on the studies confirming increased expression of COX-2 in inflammatory states, it 
is possible that a pharmaceutical that selectively targets inflammatory cells would 
decrease unwanted side effects such as GI toxicity. Additionally, it has been shown that 
COX-2 inhibitors do not prolong bleeding time.  However there are several disadvantages 
to this class of NSAIDs including financial cost and risk of abnormal coagulation, 
myocardial infarction, and cerebrovascular accidents (Khan and Dionne 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
INTRODUCTION 
 
The general population commonly associates root canal therapy with pain, and 
postoperative pain remains a frequent sequelae of endodontic treatment. While many 
patients are asymptomatic following endodontic procedures, 20% of patients experience 
moderate to severe pain (Harrison et al.1981). A recent systematic review found the 
prevalence of at least mild postoperative pain to range from 3% to 58% in sixteen 
included studies (Sathorn et al. 2008). The greatest level of postoperative pain usually 
occurs during the first 24 hours following endodontic treatment  (O’Keefe 1976). It is 
well established that high levels of preoperative pain are predictive of higher levels of 
discomfort both intra- and post-operatively after endodontic therapy  (Harrison et al. 
1983; Torabinejad et al. 1994). Many studies have been done that attempt to identify 
other factors that affect post operative pain, however very few of such factors have 
shown a significant association.  
Several factors inherent to the infected root canal and root canal therapy have 
been proposed as etiologies for postoperative pain. These include overinstrumentation of 
the canals (Harrison et al. 1983), changes in periapical pressure following root canal 
therapy (Mohorn et al. 1971), the presence of specific anaerobic bacterial species (Griffee 
et al. 1980; Gomes et al. 2008), endotoxin (Schonfeld et al. 1982) and inflammatory by-
products (Seltzer and Naidorf, 1985; Seltzer et al. 2004).  
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Individual variation in pain is likely due to a complex system of environmental 
factors and multiple gene polymorphisms. The genetic basis for acute pain conditions 
such as postoperative endodontic pain remains unknown.  Genes have been implicated in 
animal studies to account for between 28 to 76% of pain perception (Mogil 1999). While 
an increasing number of genetic variants associated with clinical pain phenotypes are 
being identified, Catechol-O-methyltransferase (COMT) has been specifically confirmed 
as a pain-modulating enzyme. COMT is among the genes encoding molecules involved 
in the monoamine neurotransmitter system (Zubieta et al. 2003). SNPs in the COMT 
gene modulate enzyme activity and consequently contribute to the individual differences 
in pain perception Four main SNPs have been identified that, when combined, formed 
three major haplotypes that explained ~ 11% of the overall variability in the test 
population’s sensitivity to pain. Different haplotype combinations corresponded to 
different levels of pain sensitivity. Subjects who were homozygous for the “low pain 
sensitivity” (LPS) haplotype had the lowest pain responsiveness. Intermediate pain 
responsiveness was observed for individuals homozygous for the “average pain 
sensitivity” (APS) haplotype.  The greatest pain responsiveness was observed for 
individuals heterozygous for the APS haplotype and “high pain sensitivity” (HPS) 
haplotype (Diatchenko et al. 2005). 
An association between genetic polymorphisms of COMT and chronic pain 
conditions has been established. Diatchenko et al. reported the incidence rate of TMD 
amongst HPS and APS subjects to be more than twice as high compared with LPS 
subjects. Persistent facial pain patients have lower COMT activity (Marbach and Levitt 
1976) The effects of variations in COMT on acute clinical pain responses in humans have 
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been examined and a significant association was found with postoperative pain levels. 
However in a study of approximately 112 patients, it was determined that genetic 
polymorphisms in the monoamine neurotransmitter systems, including COMT, contribute 
only weakly to interindividual variability in postoperative pain after third molar 
extraction (Kim et al. 2006).  
The exact mechanisms for polymorphisms in COMT function in humans have 
been identified. Nackley et al. (2006) showed that protein translation is regulated by an 
interaction between three alleles in the COMT haplotypes. The three different 
haplotypes-  HPS, APS, and LPS-- varied in mRNA structure stability, and the lowest 
COMT protein levels and enzymatic activity were associated with the most stable 
structures. Another animal study by Nackley et al. (2007) identified how COMT 
inhibition increases pain sensitivity. Rats were administered a COMT inhibitor 
(mimicking the effects on the HPS haplotype), and responses to mechanical and thermal 
stimuli were measured. They found that low COMT activity caused pain sensitivity 
through activation of the beta2-and beta3- adrenergic receptors (βARs) .  
Other potential candidate genes for pain modulation include COX-1 and COX-2. 
Cyclooxygenase 1 (COX-1; prostaglandin H synthase1; PTGS1) is the constitutively 
expressed main enzyme involved in the synthesis of prostaglandin H2 from arachidonic 
acid, which is the committed step in prostaglandin (PG) synthesis. Cyclooxygenase 
(COX-2; prostaglandin H synthase2; PTGS2) is inducible and has a role primarily in the 
production of PGs that promote inflammation. (Khan et al. 2007). The cyclooxygenases 
are also the primary targets of aspirin and non-steroidal anti-inflammatory drugs 
(NSAIDs) and thus of major interest in the management of inflammatory type pain. 
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Iburpofen is the prototypical NSAID, and is the drug of choice among endodontists for 
postoperative pain relief (Torabinejad et al. 1994).  
A study by Khan et al. (2007) examined the in vivo expression of COX-1 and 
COX-2 before and after removal of impacted mandibular third molars. Their results 
demonstrated little or no COX-2 expression preoperatively, as opposed to the COX-1 
transcript which was detected in all preoperative and postoperative specimens. They 
confirmed the results of previous studies (Lee et al. 2006) showing a significant, 
progressive postoperative increase in the level of COX-2 mRNA over time compared to 
preoperatively. The results definitely demonstrated increased expression of COX-2 in 
acute inflammation. The corresponding increase in PG levels may influence 
postoperative pain levels.  
Genetic variations of COX-1 and COX-2 have been described in several studies 
(Ulrich et al. 2002; Halushka et al. 2003, Lee et al. 2006). However, the association 
between acute postoperative pain and COX-1 and COX-2 polymorphisms has not yet 
been determined.  
 Pain is a multifactorial process, which is influenced by physiological and 
psychosocial factors. Despite suggestive evidence that genetic polymorphisms in COMT 
influence pain sensitivity, their exact roles in the perception of acute postoperative pain in 
humans are currently unknown. We conducted a study to examine determine how various 
phenotypic factors contribute to pain after endodontics and also whether a genetic 
association could be identified between COMT polymorphisms and an acute pain 
condition. The association between COX-1 and COX-2 genotype and postoperative pain 
perception was also assessed.
  
 
MATERIALS AND METHODS 
 
A.   Subjects  
The design of this study was a prospective cohort study. Patients were recruited 
from the University of North Carolina-Chapel Hill (UNC) School of Dentistry Graduate 
endodontic clinic. Twenty-five patients were recruited in the preliminary phase of the 
study, and 69 more were enrolled consecutively provided they met inclusion criteria. All 
subjects were English-speaking, over 18 years old, and required root canal therapy for 
various indications. Pretreatment pulpal diagnoses included healthy pulp, irreversible 
pulpitis, pulp necrosis or previously treated pulp. Pretreatment periapical diagnoses 
included normal apical tissues, asymptomatic or symptomatic apical periodontitis, and 
chronic or acute apical abscess. The pilot study recruits were required to be experiencing 
none or mild pre-treatment pain; the remaining subjects were enrolled regardless of 
preoperative pain level reported. Exclusion criteria included patients on corticosteroid 
medications or unable to take ibuprofen. Informed consent was obtained and the patients 
were asked to complete pre-treament questionnaires. Physiologic parameters including 
vital signs (blood pressure, heart rate) on the right arm. An algometer (kgs) was applied 
to the trapezius muscle in order to measure baseline mechanical pain sensitivity at a site 
distinct from the site of chief complaint. Salivary DNA was collected prior to the 
initiation of root canal therapy. Patients were compensated with a $10.00 Walmart gift 
 31 
 
card after postoperative questionnaires were received. This protocol was approved by the 
UNC Institutional Review Board.  
 
B.   Experimental Protocol 
  Pretreatment questionnaires were completed while sitting in the dental chair 
prior to root canal therapy being initiated.  Following patient completion of the general 
data information form, pretreatment pain log, and investigator recording of vital signs, 
algometer score, DNA was obtained in an Oragene Self-Collection System following 
manufacturer’s instructions. This system has been shown to yield high quality DNA, 
similar to that purified from blood. It is convenient, proven, and specimens remain intact 
for years in their collected media at room temperature (Birnboim 2004). 
While root canal therapy was not standardized, the basic protocol used by UNC 
endodontic graduate students is as follows: Local anesthetic is administered; rubber dam 
isolation is achieved; access to the pulp is established and working lengths radiographs 
are obtained; canals are instrumented using nickel-titanium rotary and stainless steel hand 
instruments; the canals are either obturated with Resilon/EpiphanyTM or calcium-
hydroxide was placed as an interappointment medicament. Patients were instructed that 
they may or may not experience pain following the procedure. Patients were then asked 
to complete a diary based on their level of worst pain and average pain for five 
consecutive days after treatment and three psychological questionnaires at any time after 
treatment. While no analgesics were prescribed, patients were asked to report any 
analgesics, including dosage and frequency, which may have been self-administered 
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during the postoperative period. Patients were given an addressed, stamped envelope to 
mail the forms back after completion.  
Genetic data processed at CogenicsTM Genomics Services Company (Cary, NC).  
DNA was extracted from the saliva of 93 patients using the 4 ml Oragene DNA Purifier 
System. DNA was quantified using Pico Green Assay kit to ensure DNA concentration of 
at least 10 ng/µl. SNP genotyping was performed using iPLEX Gold chemistry 
(Sequenom). SNP Assays were designed by MassARRAY Assay Design 3.1 
(Sequenom). iPLEX Gold chemistry utilizes multiplex PCR. After the PCR, remaining 
nucleotides are deactivated by SAP treatment. Then single base primer extension is 
performed, and the primer extension products are analyzed using MALDI TOF Mass 
Spectrometer. From the MALDI TOF Mass Spectrometer peak information we are able 
to accurately genotype the SNP of interest using Typer 4 software (Sequenom.) Samples 
that failed to amplify sufficiently for allelic discrimination were not included in the final 
analysis. 
 
C.   Questionnaires  
Subjects completed a series of forms including general data and medical history 
questionnaire, consent form, HIPPA authorization, and the questionnaires described 
below:  
 
a. Pretreatment Log- assessed pain levels preoperatively. Subjects reported tooth pain 
experienced in the last 24 hours (average level, highest level, lowest level, current level, 
and percentage of the waking day experiencing pain). We also quantified their current 
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pain using a Gracely scale, which is a 21 box numerical descriptor scale constructed from 
previously quantified verbal descriptors and used by a subject to define their pain 
experience (Gracely et al. 1978; Gracely et al. 1979; Petzke et al. 2005) (See Figure 3). 
We used 2 different pain scales preoperatively because the Likert scale is a measure of 
pain intensity while the Gracely box scale uses verbal descriptors and differentiates 
between the subject’s sensory perceptions of pain intensity from their affective 
experience of the pain’s unpleasant quality (Eliav et al. 1998; Lembo et al. 2000).  
 
b. Post-Operative Patient Diary- assessed the subject’s pain experience for five days 
consecutively after treatment. Subjects were instructed to complete the questionnaire 
prior to bedtime and record the time of day and the worst pain and average pain they felt 
in the teeth or mouth during the past 24 hours (on a Likert scale with the anchors “No 
pain” and “Worst pain imaginable”).  Likert pain scales are a method widely accepted 
and used in dental research and a valid tool for the current application (Seymour 1982; 
Cepeda 2003). Medication intake was also assessed including whether or not medication 
was taken to relieve pain or swelling and the name of the medication, strength in 
milligrams, and number of pills taken.   
 
 c. Beck Depression Index (BDI; Beck et al. 1961)- this 21-question multiple choice 
inventory provided a measure of the severity of depression. Parameters measured from 
this test included symptoms of depression such as hopelessness, irritability, guilt, feelings 
of being punished, fatigue, weight loss, and lack of interest in sex. The BDI has 
demonstrated adequate reliability and validity and has been used widely in a variety of 
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clinical populations. The following ranges of intensity are used to screen subjects for 
depression: normal (0–9); mild depression (10–15); mild to moderate depression (16–19); 
moderate to severe depression (20–29); and severe depression (30+). 
 
d.  Pennebaker Inventory of Limbic Languidness (PILL; Pennebaker 1992) assessed 
somatization by capturing the frequency of occurrence of  54 common physical 
symptoms and sensations on a 6-point Likert-type scale. The PILL contains a range of 
physical symptoms, including some items that are pain-related (e.g., headache, back 
pains, sore muscles). It has a reported high internal consistency and adequate test-retest 
reliability (0.70 for a 2 month period). The PILL is conceptualized as a trait-like 
symptom scale that evaluates a general propensity to report physical symptoms 
(Pennebaker 1982).  
 
e. State-Trait Anxiety Inventory Y-2 (STAI-Y2; Spielberger et al. 1983) assessed 
situational and generalized anxiety. This 40-item test clearly differentiates between the 
temporary condition of state anxiety and the more general and long-standing quality of 
trait anxiety.  The STAI-Y2 has been validated and is widely used to assess anxiety in 
medical settings. 
 
D.  Statistical Analysis 
Data was analyzed with R. software (version 2.8.1; 2008, Vienna, Austria) and 
statistical significance was set at p < 0.05. All mean values are reported as + standard 
error. Pearson correlations were performed to assess the relationship between the 
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measures of postoperative pain and genetic variables. Repeated measures analysis of 
variance (ANOVA) was also performed to examine the effects of individual SNPs on 
pain response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
RESULTS 
 
A.  Group Profile  
All patients recruited for this investigation presented to the UNC-School of 
Dentistry for root canal therapy (RCT) by graduate endodontic residents. Ninety-four 
patients total were enrolled in the study and had their baseline information and salivary 
DNA collected. Twenty-five subjects were enrolled in the preliminary phase of the study; 
sixty-nine subjects were enrolled in the second phase of this study. Only two people 
refused participation when asked to enroll. Six patients had the tooth that was treatment 
planned for root canal therapy sent for extraction due to patient choice or the tooth was 
determined unrestorable, so they were unable to complete their entries. Fourteen 
participants did not return their postoperative forms. This resulted in 74 completed 
entries. Fifty-three of these completed subjects were enrolled in the second phase of the 
study. 
Table 1 displays the demographics and baseline characteristics of the 69 subjects 
enrolled in the main phase of this study. Thirty nine (57%) of subjects were males and 30 
(43%) were females. The mean age for all subjects was 48 + 2.19 years. The age range 
for subjects was 18 to 85 years.  The majority of participants were Caucasian (70%) 
however Black, Hispanic, and Asian patients also enrolled in the study. Only 12 subjects 
(17%) reported preoperative pain within the past 24 hours on the day of enrollment. 
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Pretreatment periapical diagnoses included normal apical tissues; symptomatic and 
asymptomatic apical periodontitis; and acute and chronic apical abscess. Forty-two 
subjects (61%) had periapical disease, and 35 (51%) had a periapical radiolucency 
present on the initial radiograph. There were no statistically significant differences 
between male and female subjects in any of the demographic characteristics measured.  
 All teeth types being endodontically treated were included in this study. Table 4 
lists the distribution of tooth type between male and female subjects. The majority of 
treated teeth (66%) were molars. An equal number of teeth were treated in the maxillary 
and mandibular arches. There was no significant difference in treated tooth type between 
males and females (p = 0.887).  
 
B.   Preoperative Pain Level and Baseline Physiologic Data  
Of the 12 subjects who experienced pain at the time of enrollment in the study, 
half were males and half were females. Further quantification of preoperative pain is 
shown in Table 2. The mean highest level of pain experienced on a scale of 0 (No pain) 
to100 (most intense pain possible) was 51 + 9.54. The mean percentage of the day that 
subjects experienced pretreatment pain was 50% + 10.78%. We did not find a significant 
association between pretreatment pain and any of the baseline demographic variables 
including subject age (p = 0.937), gender (p = 0.751), race (p = 0.108), or presence of 
periapical radiolucency (p = 0.7524).  
Physiologic data is also presented in Table 2, distributed by gender. The overall 
mean systolic blood pressure was 127.3 + 2.18 and the mean diastolic blood pressure was 
77.0 + 1.23. Mean heart rate was 69.4  + 1.79 beats/minute. Baseline experimental pain 
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sensitivity was measured by algometer score on a scale of 0.00 to >5.0 kg; mean 
algometer score was 3.24 + 0.12. Preoperative pain level was not associated with systolic 
blood pressure (p = 0.757), diastolic blood pressure (p = 0.353), heart rate (p = 0.420) or 
algometer score (p = 0.804).  
 
C.   Postoperative Pain Levels and Pain Medication Intake 
The course of mean postoperative endodontic pain by gender is shown in Figure 
4. Sixty-three percent of subjects reported at least mild pain postoperatively. Reported 
mean worst pain intensity decreased gradually over the five day period. Most subjects (N 
= 45; 88%) were pain-free by Day 5. The daily averages for worst pain intensity for the 
five days ranges from 0.27 to 1.88 on a Likert-scale of 0 (No pain) to 9 (Worst pain 
imaginable). For those patients who did experience postoperative pain, the average worst 
pain scores decreased from 2.91 (Day 1) to 2.17 (Day 5). The incidence of postoperative 
pain in males and females also decreased steadily over time.  On postoperative Day 1, 18 
male subjects (60%) and 16 female subjects (70%) reported at least mild postoperative 
pain. By postoperative Day 3 the number of subjects reporting postoperative pain were 
roughly cut in half (N=10 (33%) and N = 7 (30%) for males and females, respectively). 
By postoperative Day 5 only 3 males (10%) and 3 females (14%) reported postoperative 
pain. (Figure 5) All but one patient reported none or mild pain (0-3) on postoperative Day 
5.  
Twenty subjects (39%) reported taking oral analgesics for postoperative pain on 
Day 1. At 48 hours post-treatment only 9 subjects (18%) took pain medication and only 2 
patients (4%) were taking analgesics by postoperative Day 5. All but 1 subject who used 
 39 
 
post operative analgesics took NSAIDs (ibuprofen = 18 subjects (78%), naproxen = 4 
subjects (17%)).   
D.   Phenotypic Factors Associated with Postoperative Pain Level 
a. Baseline/Demographic Factors  
None of the demographic characteristics were found to be associated with 
mean Day 1 worst pain or average pain scores including subject age (p = 0.64), 
gender (p = 0.28), race (p = 0.38), dental arch treated (p = 0.56) or presence of 
periapical disease (p = 0.13) or radiolucency (p = 0.26). 
 The relationship between preoperative pain and pain on postoperative 
Day 1 is shown in Table 3. Fifty-nine percent (n = 25) of subjects who did not 
experience pretreatment pain did experience at least mild postoperative pain on 
Day 1, while 78% (n = 7) of subjects who experienced preoperative pain 
experienced pain postoperatively as well. No statistically significant difference 
was seen between male and female subjects (p = 0.569).  No significant 
association was seen between preoperative pain and incidence of pain 
postoperatively (p = 0.463). However we did find a significant association 
between presence of preoperative pain and higher intensity of reported mean Day 
1 worst pain level (p = 0.017; R2 = 0.10).  
b. Physiologic Factors 
A significant association was found between diastolic arterial blood pressure 
and mean Day 1 average pain (p = 0.024). We also found an association between 
resting heart rate and Day 1 average pain (p = 0.020). Diastolic blood pressure and 
heart rate were not significantly associated with Day 1 worst pain level (p = 0.14 and 
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p = 0.07 respectively). Systolic arterial blood pressure was not shown to be 
significantly associated with postoperative worst or average pain on Day 1 (p = 0.21 
and p = 0.15). Algometer measures were not found to be associated with mean 
postoperative pain levels (average or worst pain) on Day 1 (p = 0.611).  
c. Psychological Factors 
The mean scores for the four psychological questionnaires distributed by gender 
are shown in Table 6. The Beck Depression Index (BDI) is scored from 0 to 63, and the 
mean score in this study was 5.33 + 0.79. Scores on the Pennebaker Inventory of Limbic 
Languidness (PILL) can range from 0 to 216; the mean score was 33.24 + 3.06. Both the 
State scale (-S) and Trait scale (-T) of the State-Trait Anxiety Inventory (STAI) score 
range from 20 to 80. In this study the average STAI-S score was 30.24 + 1.34 and the 
average STAI-T was 31.46 + 1.25. There was no significant difference between male and 
female subjects in any of the scores on the psychological questionnaires (BDI: p = 0.220; 
PILL: p = 0.547; STAI-S: p = 0.386; STAI-T: p = 0.243).  
 Mean STAI-T score was found to be associated with Day 1 worst pain level (p = 
0.036).  BDI score, PILL score, and STAI- S score were not found to be significantly 
associated with mean Day 1 worst pain level (p = 0.24; p = 0.24, and p = 0.16 
respectively) or mean Day 1 average pain level (p = 0.25; p = 0.56, and p = 0.25 
respectively). 
 
E.   Genetic Data and Pain Levels  
The genotype frequencies of each tested SNP in COMT, COX-1, and COX-2 are 
shown in Table 8. For the acute pain state tested in this study, COX-1 SNP rs1236913 
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showed significant association with worst pain rating on Day 1 postoperative. 
Homozygous C/C patients of SNP rs1236913 rated their worst postoperative pain (N = 
47, mean 1.7 , s.e.0.3 ) lower (ANOVA, R2 = 0.074, p = 0.05) than those of C/T 
heterozygotes (N = 4, mean 3.8, s.e.1.0). Other SNPs present in COX-2 and COMT 
shown a trend toward association with mean Day 1 Worst postoperative pain levels, 
however no significant associations between acute pain and COX-2 or COMT genetic 
variations was found in this study (Figure 6).  
Haplotype reconstruction of the COX-1 and COMT genes did not yield 
significant associations with postoperative pain levels. One haplotype of the COX-2 gene 
was significant (p = 0.025) with Day 1 worst pain postoperative. This haplotype consisted 
of the following alleles at the various SNPs: rs2206593 = A; rs5275 = T, rs5272 = A, 
rs5277 = G, rs2383515 = G.  However, a chi squared test which examined all haplotypes 
fell short of significance.  
 
 
 
 
 
 
 
 
  
 
DISCUSSION 
 
 
 In this study we sought to identify factors that contribute to the incidence and 
intensity of postoperative pain in endodontic therapy, and specifically a genetic 
component should one exist. The occurrence of postoperative pain may delay the 
resumption of a patient’s normal activities and may lessen the likelihood of patients 
seeking dental treatment in the future. Studies have shown that patients who experience 
postoperative pain are significantly more likely to have the tooth extracted (Wong et al. 
1992).  
 We designed this study to be a prospective cohort study of accessible patients that 
presented to the UNC School of Dentistry for root canal therapy by graduate residents.  
The main advantages of prospective studies are: that they offer a direct method of 
evaluation of disease incidence; the time sequence of events is consistent with the natural 
history of disease development; they provide an efficient method of investigating 
potential associations between a disease and associated factors; and they are less prone to 
observer and respondent biases. (Torabinejad et al. 1994). A prospective study design is 
preferable for studies of common conditions, such as postoperative pain, that are likely 
due to many genes of small effect; these studies allow the examination of key gene-
environment interactions and greater validity in estimates of genetic effects (Manolio et 
al. 2006). Our goal in this prospective study was to compare the postoperative pain 
outcomes of patients with different genetic make-ups under well-controlled clinical 
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parameters. 
 In this study, the history of emergency dental treatment, including type of 
treatment and time since emergency visit, was not standardized. Because of the limited 
sample size of these cases their significance could not be evaluated. Our data showed that 
only 17% of patients presented for their initial RCT visit with preoperative pain. This is 
in contrast to studies that show up to 60% of patients presenting for endodontic treatment 
with pain (Torabinejad et al. 1994; O’Keefe 1976). The large discrepancy in our study 
between the percentages of patients presenting with preoperative pain is likely due to 
emergency treatment having been performed prior to the start of root canal therapy. In 
fact, in this study 46% of patients had a previous pulpotomy, pulpectomy, or gross pulpal 
debridement performed on the tooth being treated. We included teeth undergoing initial 
root canal therapy as well as nonsurgical retreatment, as large studies have demonstrated 
no difference regarding the incidence of postoperative pain between treatment and 
retreatment (Siqueira et al. 2002).   
 In the present study incidence and intensity of pain after nonsurgical root canal 
treatment reached its maximum within the first 24 hours of treatment, when 63% of 
patients reported pain (mean = 1.88 + 0.28), which then progressively decreased during 
the following five days. This data is supported by observations made by Georgopoulou et 
al. who reported 68% of RCTs to be associated with postoperative pain (1986) and 
Walton and Ciappinelli (1993) who found a 70% incidence of at least mild pain. A 
similar pattern of decreasing pain over time was reported by Harrison et al. (1983), 
Albashaireh and Alnegrish (1998) and Torabinejad et al. (1994).  Genet et al. (1986) 
showed very little postoperative pain 3 days after root canal therapy. Our results showed 
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that at postoperative Day 3 more than 30% of patients still reported at least mild pain. 
Twelve patients (24%) reported Day 1 worst pain levels of more than four out of a nine 
point Likert scale. Seventeen percent of the patients in the Georgopoulou study (1986) 
reported symptoms of a severe nature. Twenty subjects in our study felt the need to 
control their postoperative pain symptoms with analgesics; nineteen of them took non-
steroidal anti-inflammatory drugs (NSAIDs), with ibuprofen being the most frequently 
used analgesic.  
The results of this study did not show a difference in pain levels in teeth with or 
without periapical radiolucency. This finding is in agreement with those of Harrison et al. 
(1983), Georgopoulou et al. (1986) and O’Keefe (1976) but disagree with those of 
Marshall and Liesinger (1993), who found that patients with no radiographic periapical 
lesions had significantly more pain than patients with lesions. The age and sex of the 
patient and dental arch treated appeared not to influence the incidence of pain; this is in 
accord with the results of Harrison et al. (1983), Georgopoulou (1986), O’Keefe (1976) 
and Albashaireh and Alnegrish (1998). As far as type of tooth is concerned, the results do 
not lead to any specific conclusion because the numbers of teeth in each group are too 
small. The teeth were selected at random and the results perhaps demonstrate the varying 
need for specialist-level endodontic treatment of different teeth. Mandibular incisors 
appear to rarely need endodontic treatment compared with maxillary incisors (Table 4).  
We found in this study a strong association between preoperative pain and 
postoperative pain. Specifically, the intensity of preoperative pain was correlated with 
more severe pain on postoperative Day 1 ((p = 0.017). Furthermore, we found that 10% 
of worst pain on postoperative Day 1 could be explained by the presence or absence of 
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pretreatment pain (R2 = 0.10). This finding is consistent with most previous endodontic 
pain studies that assessed the effect of preoperative pain on postoperative pain 
(Torabinejad et al. 1994; O’Keefe 1976; Genet et al. 1986).  
Our study identified an association between blood pressure, heart rate, and 
postoperative pain for the first time in a clinical endodontic setting. The exact mechanism 
for the contribution of arterial blood pressure to experimental pain sensitivity remains 
unknown. One proposed mechanism involves activation of the carotid sinus 
baroreceptors (Mini et al. 1995). That higher resting blood pressure is associated with 
decreased pain sensitivity is well-established (Fillingim and Maixner 1996; Maixner et al. 
1997).  Specifically normal, pain-free subjects with higher blood pressures at rest have 
higher pain threshold and tolerance compared with subjects with lower blood pressures 
(Maixner et al. 1997). 
In this study, we enrolled subjects of several different ethnic populations, rather 
than using only Caucasian patients in our cohort. However the number of subjects in all 
racial groups other than Caucasians was very small. A potential problem with this is that 
it is well-known that allele frequencies of functional variants often differ greatly among 
groups with different ancestries (Daar and Singer 2005). In order to generalize our 
findings to other ethnic groups, further studies with more enrollment from subjects in 
other major ethnic population groups are needed. The ethnicity of subjects was self-
determined on an initial general data form; this is an acceptable method for determining 
subject ethnicity, but less reliable than using explicit genetic data such as DNA (Kim et 
al. 2006).  
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 Three psychological questionnaires were used to assess the subjects in this study. 
The Beck Depression Inventory (BDI; Beck et al. 1961) has been evaluated as a 
measurement tool in patients with chronic pain. It was found that the BDI is an excellent 
screening tool for patients with chronic pain, and in particular a score above 22 is the 
optimum cut-off score for depression in pain patients (Poole et al. 2009).  In this study 
the mean BDI score was 5.16 + 0.79. Studies show that chronic pain patients score higher 
on the BDI than pain-free controls (Conrad et al. 2007). A study of 135 patients with 
acute jaw pain found that the BDI score average in this population is 8.56 + 8.30 
(Edwards et al. 2006).  It has recently been reported that fibromyalgia patients showed 
lower pressure pain thresholds and tolerances and higher scores on the Pennebaker 
Inventory for Limbic Lanugidness (PILL; Pennebaker 1982) compared to arthritis 
patients and pain-free controls (McDermid et al. 1996). A high somatization score on the 
PILL is an independent risk factor for the development of a chronic pain state 
(Diatchenko et al. 2006).  In this study, neither the BDI nor the PILL scores were 
correlated with postoperative pain. The State-Trait Anxiety Inventory (STAI-Y2; 
Spielberger et al. 1983) measures a patient’s general propensity to experience anxiety. 
Studies have shown that patients with chronic musculoskeletal pain report increased 
amounts of psychological distress on the STAI-Y2 form compared to healthy people 
(Huber et al. 2008). However, chronic pain patients have been shown to score higher on 
the state anxiety portion of the form versus pain-free controls (Conrad et al. 2007).  In 
this study, while no correlation was seen between state anxiety on the STAI-Y2 form and 
postoperative pain, a significant association was seen been trait anxiety score and mean 
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worst pain on postoperative Day 1 (p = 0.036).  Patients with higher STAI-T scores, 
indicating higher trait anxiety, had higher mean worst pain on Day 1.  
In this study we identified one SNP (rs1236913) in the COX-1 gene that was 
found to be nominally associated with mean worst pain scores on postoperative Day 1 (p 
= 0.05). This SNP is located in exon 2, and substitutes amino acids (R8W) (Takahashi et 
al. 2007; Shi et al. 2005) which suggests a possible impact on protein function (Siezen et 
al. 2006).  However, after correction for multiple comparisons this result is unlikely to be 
significant.  Our results also demonstrate a trend toward significance of association 
between a few other SNPs on the COX-1, COX-2, and COMT genes (See Figure 5). 
Specifically the rs2206593 SNP on COX-2 has been identified as a tagging SNP 
(Danforth et al. 2008). This SNP has been shown to be marginally associated with 
prostate cancer risk (Cheng 2007).  The SNP rs1544325 on COMT has been proposed to 
play a role in the onset of schizophrenia (Chulwon et al. 2007). Finally, SNP rs165774 is 
located on the fifth intron of the COMT gene. It has been linked to mental retardation 
(Zhange et al. 2007) and fibromyalgia (Garcia-Fructuoso et al. 2008). These SNPs may 
be candidates for important genetic polymorphisms in acute pain conditions as well.  
While one COX-2 haplotype came up as significant (p = 0.025) for postoperative 
pain, a subsequent chi-squared test which examined all haplotypes fell short of 
significance. Therefore, while there may be an association present, our results are 
preliminary. Further studies would be needed to reproduce this result.  
 The present study likely has insufficient power to detect more than trends in 
genetic associations with postoperative pain. Difficulty recruiting subjects within the 
available time frame contributed to this study being underpowered. Specifically, many 
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patients treated in the UNC School of Dentistry graduate endodontics clinic were 
ineligible for enrollment due to age, inability to take ibuprofen, or extensive emergency 
therapy being completed so that only obturation was taking place.  In the future we feel 
we need to enroll more patients in the cohort to obtain significant conclusions. If the 
study population was to be expanded and significant associations are found, future 
studies would then be necessary to replicate these findings.  
Understanding acute pain conditions on a genetic level has important implications 
for their future management. NSAIDs that target COX-1 and COX-2 are the frontline 
therapy for post-treatment pain in endodontics. The discovery of functional 
polymorphisms in the COX genes may ultimately improve the safe and effective use of 
NSAIDS by better tailoring drug dosage in accordance with an individual’s genetic 
variation.  
The identification of polymorphisms associated with postoperative pain may be 
useful in the future to define individuals on the basis of genetic variations to predict 
patient risk of postoperative pain and benefit to drugs. Identifying a specific gene that 
affects pain perception may one day lead to the creation of individualized treatments that 
will reduce the morbidity of pain conditions.  
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Figure 1. COMT gene with tested SNP location (rs165774; rs1544325; rs165599; rs6269; 
rs4680; rs174697; rs2020917; rs11569716; rs737865) on chromosome 22. 
 
 
 
 
 
Figure 2. (a) COX-1 gene with tested SNP location (rs1236913; rs3842803; rs10306202;  
rs5789; rs10306114; rs1213266; rs3842788) on chromosome 9.  
 
 
(b) COX-2 gene with tested SNP location (rs2206593; rs2383515; rs5275; rs5277) on 
chromosome 1.  
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Table 1: Demographics and Baseline Characteristics of Enrolled Subjects  
BASELINE 
CHARACTERISTIC 
SUBJECTS- 
MALES 
SUBJECTS- 
FEMALES 
OVERALL 
Total Enrolled (n) 39 (57)  30 (43)  69 
Average Age (years) 54 + 3.02 42 + 2.80 48 + 2.19 
Racial Distribution*    
                                       White  27 (69) 21 (70) 48 (70) 
                                       Black 4 (10) 3 (10) 7 (10) 
                                  Hispanic 5 (13) 2 (7) 7 (10)  
                                       Asian 2 (5) 4 (13) 6 (9) 
                                       Other 1 (3) 0 (0) 1 (1) 
Subjects with Pretreatment Pain 6 (15) 6 (20) 12 (17) 
Subjects without Pretreatment 
Pain 
33 (85) 24 (80) 57 (83) 
Presence of Periapical Disease 25 (64) 17 (57) 42 (61) 
Presence of Periapical 
Radiolucency  
22 (56) 13 (43) 35 (51) 
*Values are expressed as number (percentage) unless otherwise indicated  
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Table 2: Physiologic and Pain Characteristics at Baseline: Males and Females 
 
 Males Females Overall  
Subjects presenting with pre-
operative pain* 
6 (15) 6 (20) 12 (17) 
Current pain level** 28 (12.5) 19 (8.80) 24  (7.41) 
Average level of pain in the last 24 
hours** 
37 (9.55)  40 (10.65) 38 (6.83) 
Highest level of pain in the last 24 
hours** 
52 (15.26) 51 (12.93) 51 (9.54) 
Lowest level of pain in the last 24 
hours** 
13 (5.58) 17 (9.89) 15 (5.45) 
Percentage of the day Subject 
experienced pain 
56 (15.40) 44 (16.16) 50 (10.78) 
Gracely Scale    
                                        Intensity 8.8 (3.15) 6.8 (3.09) 7.8 (2.12) 
                             Unpleasantness 7.3 (2.63) 6.0 (2.14) 6.7 (1.63) 
Blood Pressure- Systolic***  132.9 (2.71) 120.1 (3.14) 127.3 (2.18) 
Blood Pressure- Diastolic  78.8 (1.71) 74.7 (1.70) 77.0 (1.23) 
Heart Rate (beats/min) 66.6 (1.97) 73.0 (3.15) 69.4 (1.79) 
Algometer Score (kg) 3.54  (0.15) 2.85 (0.19) 3.24 (0.12) 
*Value expressed as N Subjects/Total N (percentage) 
**Values are expressed as mean score % (standard error of the mean) unless otherwise 
indicated; Pain is expressed as a number from 0 (No pain) to 100 (Most intense pain 
imaginable) 
***N = 69 and includes all subjects enrolled in phase 2 of the study, regardless of 
preoperative pain level  
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Table 3: Relationship between preoperative pain and pain on 1st postoperative day: Males 
and Females 
Group No Preoperative 
Pain 
 
Postoperative 
Pain 
Preoperative Pain  Postoperative 
Pain 
 N* (%) N (%) N (%) N (%) 
Males 24 (83) 14 (58) 5 (17) 3 (60) 
Females 18 (82) 11 (61) 4 (18) 4 (100) 
Overall 42 (82) 25 (59) 9 (18) 7 (78) 
*Total N = 51 (number of completed entries)  
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Table 4: Tooth distribution between Males and Females  
    Males      Females        Overall 
Tooth Type       N*           (%)          N      (%)           N       (%) 
 
Maxillary anteriors           5          (13)            4     (13)            9      (13)        
Maxillary premolars         4           (11)           0      (0.0)          4      (6) 
Maxillary molars              11          (29)            11     (36)            22      (32) 
Mandibular anteriors        1           (3)           0      (0.0)          1       (2) 
Mandibular premolars      7           (8)           2      (6.7)          9                (13) 
Mandibular molars           10           (26)           13      (43)           23              (34) 
 
*Total N = 68 teeth  
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Table 5: Postoperative Pain Course: Males and Females  
a) All Subjects (N=51) 
 Males Females Overall  
Subjects experiencing Post-
operative pain* 
17 (59) 15 (68) 32 (63) 
Day 1    
                         Worst pain level** 1.60 (0.35) 2.22 (0.47) 1.88 (0.28) 
                     Average pain level   0.97 (0.23) 1.48 (0.33) 1.18 (0.19) 
Day 2     
                          Worst pain level 0.83 (0.21) 0.87 (0.33) 0.85 (0.19) 
                      Average pain level   0.66 (0.15) 0.87 (0.30)  0.78 (0.16) 
Day 3        
                            Worst pain level 0.67 (0.26) 1.04 (0.42) 0.86 (0.23) 
                         Average pain level 0.43 (0.20) 0.70 (0.28) 0.57 (0.16) 
Day 4       
                            Worst pain level  0.53 (0.31) 0.59 (0.31) 0.58 (0.22) 
                          Average pain level   0.33 (0.24) 0.50 (0.25) 0.43 (0.17) 
Day 5        
                            Worst pain level  0.14 (0.08) 0.41 (0.32) 0.27 (0.15) 
                          Average pain level 0.03 (0.03) 0.36 (0.28) 0.18 (0.12) 
 
a) Among Patients experiencing pain (N=32) 
 Males Females Overall  
Day 1    
                         Worst pain level** 2.67 (0.42) 3.19 (0.50) 2.91 (0.32) 
                     Average pain level   1.81 (0.29) 2.43 (0.36) 2.10 (0.23) 
Day 2     
                          Worst pain level 2.03 (0.34) 2.55 (0.50) 2.23 (0.28) 
                      Average pain level   1.36 (0.17) 2.22 (0.49) 1.70 (0.23) 
Day 3     
                            Worst pain level 2.00 (0.60) 3.43 (0.90) 2.59 (0.52) 
                         Average pain level 1.86 (0.59) 2.29 (0.57) 2.07 (0.40) 
Day 4    
                            Worst pain level  2.67 (1.31) 2.60 (0.93) 2.64 (0.79) 
                          Average pain level   3.33 (1.86) 2.20 (0.73) 2.63 (0.78) 
Day 5     
                            Worst pain level  1.33 (0.33) 3.00 (2.00) 2.17 (0.98) 
                          Average pain level 1.00 (NA) 2.67 (1.67) 2.25 (1.25) 
*Value expressed as N Subjects/Total N (percentage) 
**Values are expressed as mean score % (standard error of the mean) unless otherwise 
indicated; Pain was expressed on a 9-point Likert scale with anchors 0 (No Pain) to 9 
(Worst pain imaginable) 
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Table 6: Psychological Output Variable Distribution: Males and Females 
 
Psych test  Males Females  Overall 
BDI* 4.46 (0.73) 6.48 (1.54) 5.33 (0.79) 
PILL  31.79 (3.16) 35.35 (5.99) 33.24 (3.06) 
STAI-S  29.03 (1.70) 31.82 (2.14) 30.24 (1.34) 
STAI-T 30.00 (1.30) 33.32 (2.26) 31.46 (1.25) 
*Average score as expressed by mean (standard error of the mean) 
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  Number 
in Group 
None Mild Moderate/Severe 
  N (%) N (%) N (%) 
Males 29 12 (41) 12 (41) 5 (17) 
Females 22 7 (32) 8 (36) 7 (32) 
Overall 51 19 (37) 20 (39) 12 (24) 
Definition of Terms based on Likert Scale Rating: None = 0, Mild = 1-3, Mod/Severe= 4-9 
 
Table 7: Incidence of worst pain on 1st post treatment day by gender   
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SNPs Genotype Number of 
subjects 
Genotypes 
Frequencies 
Mean (SE) 
Worst Pain  
ANOVA  
R2 
P-value Gene 
rs2206593 A/G 6 0.118 3.7 (0.8) 0.064 0.07 COX-2 
 G/G 45 0.882 1.6 (0.3)    
rs2383515 G/G 29 0.569 2.3 (0.4)  0.037 0.18 COX-2 
 G/T 22 0.431 1.3 (0.4)    
rs5275 C/C 7 0.200 1.3 (0.7) 0.073 0.30 COX-2 
 C/T 15 0.429 1.5 (0.5)    
 T/T 13  0.371 2.8 (0.5)    
rs5277 C/C 1 0.020 2.0 (2.1) 0.0003  0.99 COX-2 
 C/G 12 0.235 1.5 (0.6)    
 G/G 38 0.745 2.0 (0.3)    
rs1236913 C/C 47 0.922 1.7(0.3) 0.074 0.05* COX-1 
 C/T 4 0.078 3.8(1.0)    
rs3842803 C/T 2 0.039 0.0(1.5) 0.028 0.24 COX-1 
 T/T 49 0.961 2.0(0.3)    
rs10306202 A/A 1 0.020 0.0(2.1) 0.052 0.28 COX-1 
 A/G 11 0.216 2.5(0.6)    
 G/G 39 0.765 1.8(0.3)    
rs5789 A/C 1 0.020 0.0(2.0) 0.014 0.37 COX-1 
 C/C 50 0.980 1.9(0.3)    
rs10306114 A/A 44 0.863 2.0(0.3) 0.038 0.40 COX-1 
 A/G 5 0.098 1.2(0.9)    
 G/G 2 0.039 0.5(1.5)    
rs1213266 A/A 1 0.020 0.0(2.1) 0.018 0.64 COX-1 
 A/G 10 0.196 1.9(0.7)    
 G/G 40 0.784 1.9(0.3)    
rs3842788 A/A 1 0.020 0.0(2.1) 0.015 0.70 COX-1 
 A/G 10 0.196 1.9(0.7)    
 G/G 40 0.784 1.9(0.3)    
rs165774 A/A 3 0.059 3.7(1.2) 0.11 0.06 COMT 
 A/G 17 0.333 1.2(0.5)    
 G/G 31 0.608 2.1(0.4)    
rs1544325 A/A 4 0.078 0.0(1.0) 0.099 0.08 COMT 
 A/G 25 0.490 2.4(0.4)    
 G/G 22 0.431 1.7(0.4)    
rs165599 A/A 17 0.333 2.2(0.5) 0.059 0.24 COMT 
 A/G 27 0.529 2.0(0.4)    
 G/G 7 0.137 1.0(0.8)    
rs6269 A/A 13 0.255 2.5(0.6) 0.055 0.25 COMT 
 A/G 26 0.510  1.5(0.4)    
 G/G 12 0.235 1.9(0.6)    
rs4680 A/A 8 0.157 2.6(0.7) 0.032 0.46 COMT 
 A/G 23 0.451 1.7(0.4)    
 G/G 20 0.392 1.8(0.5)    
rs174697 A/G 9 0.176 1.4(0.7) 0.0089 0.51 COMT 
 G/G 42 0.824 2.0(0.3)    
rs2020917 C/C 23 0.451 1.6(0.4) 0.016 0.68 COMT 
 C/T 20 0.392 2.3(0.5)    
 T/T 8 0.157 1.8(0.7)    
rs11569716 C/T 2 0.039 1.5(1.5) 0.0021 0.75 COMT 
Table 8. Variation in pain levels (mean worst pain score) among tested SNPs of the COMT, COX-
1, and COX-2 genes  
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 T/T 49 0.961 1.9(0.3)    
rs737865 C/C 7 0.137 2.0(0.8) 0.0036 0.92 COMT 
 C/T 22 0.431 2.1(0.5)    
 T/T 22 0.431 1.6(0.5)    
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Figure 3. Gracely scale used to measure subject’s pretreatment pain level.  
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 Figure 4a. Course of Mean Worst Postoperative Pain in Male (N=30) and Female (N = 
23) Subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4b. Course of Mean Worst Postoperative Pain in Male and Female Subjects who 
reported pain postoperatively (N total = 32). 
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Incidence of Postoperative Pain Over Time
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Figure 5. Percentage of Male (N=30) and Female (N=23) with Pain on Postoperative 
Days 1-5.  
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Mean Worst Day 1 Postoperative Pain Rating and 
SNPs from COMT, COX-1 and COX-2
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Figure 6. Mean Worst Day 1 postoperative pain rating (0-9) and selected SNPs from 
COMT, COX-1, and COX-2. COMT: catechol-O-methyltransferase gene; COX-1: 
cyclooxygenase-1 gene; COX-2: cyclooxygenase-2 gene  
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